A Phase II Study of High-Dose-Rate Afterloading Brachytherapy as Monotherapy for the Treatment of Localized Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 2, 2008, Pages 441-446

  Corner, Carie ^a   Rojas, Ana Maria ^a   Bryant, Linda ^a   Ostler, Peter ^a   Hoskin, Peter ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Afterloading brachytherapy; Dose escalation; High dose rate monotherapy; Localized prostate cancer; Phase II study

Indexed keywords

AFTERLOADING BRACHYTHERAPY; DOSE ESCALATION; HIGH-DOSE-RATE MONOTHERAPY; LOCALIZED PROSTATE CANCER; PHASE II STUDY;

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AGED; ARTICLE; BLADDER DISCOMFORT; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; ENTEROPATHY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; URETHRAL CATHETERIZATION;

ANDROGEN ANTAGONISTS; BRACHYTHERAPY; GASTROINTESTINAL TRACT; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; URINARY BLADDER;

EID: 51449100864     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.12.026     Document Type: Article

References (28)

1. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomised trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
2. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated dose versus standard dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
3. Sylvester J. High dose rate versus low dose rate monotherapy in the treatment of localised prostate cancer. The case for high dose rate monotherapy: An up and coming treatment option for low risk prostate cancer. Brachytherapy 5 (2006) 1-4
4. Stock R.G., Stone N.N., Tabert A., et al. A dose response study for iodine 125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
5. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
6. Wallner K., Merrick G., True L., et al. 125I versus 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 57 (2003) 1297-1303
7. Peschel R.E., Colberg J.W., Chen Z., et al. Iodine 125 versus palladium 103 implants for prostate cancer: Clinical outcomes and complications. Cancer J 10 (2004) 170-174
8. Hoskin P.J. High dose rate brachytherapy boost treatment in radical radiotherapy for prostate cancer. Radiat Oncol 57 (2000) 285-288
9. Pellizzon A.C., Nadalin W., Salvjoli J.V., et al. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol 66 (2003) 167-172
10. Galalae R.M., Martinez A.A., Mate T., et al. Long term outcome by risk factors using conformal high dose rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1048-1055
11. Chin Y.S., Bullard J., Bryant L., et al. High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol) 18 (2006) 474-479
12. Grills I.S., Martinez A.A., Hollander M., et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171 (2004) 1098-1104
13. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
14. Fowler J., Chappell R., and Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
15. Wang J.Z., Li X.A., Yu C.S., et al. The low alpha/beta ratio for prostate cancer: What dose the clinical outcome of HDR brachytherapy tell us?. Int J Radiat Oncol Biol Phys 57 (2003) 1101-1108
16. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol 19 (2007) 289-301
17. Hoskin P.J., and Dearnaley D.P. Hypofractionation in Clinical trials for prostate cancer. Clin Oncol 19 (2007) 287-288
18. Martinez A.A., Pataki I., Edmundson G., et al. Phase II prospective study of the use of conformal high dose rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 49 (2001) 61-69
19. Yoshioka Y., Nose T., Yoshida K., et al. High dose rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys 56 (2003) 213-220
20. Martin T., Baltas D., Kurek R., et al. 3-D conformal HDR brachytherapy as monotherapy for localised prostate cancer. A pilot study. Strahlenther Onkol 180 (2004) 225-232
21. Hoskin P.J. High dose-rate afterloading brachytherapy for prostate cancer. In: Joslin C., Flynn A., and Hall E. (Eds). Principles and practice of brachytherapy using afterloading systems (2001), Arnold, London 257-265
22. Hoskin P.J., Bownes P.J., Ostler P., et al. High dose rate afterloading brachytherapy for prostate cancer: Catheter and gland movement between fractions. Radiother Oncol 68 (2003) 285-288
23. Barry M.J., Fowler Jr. F.J., O'Leary M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148 (1992) 1549-1564
24. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Publish date August 9, 2006. Available at: http://ctep.cancer.gov/reporting/ctc_v30.html. Accessed January 7, 2008.
25. King C.R., DiPetrillo T.A., and Wazer D.E. Optimal radiotherapy for prostate cancer: Predictions for conventional external beam, IMRT and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys 46 (2000) 165-172
26. Kupelian P.A., Willoughby T.R., and Reddy C.A. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68 (2007) 1424-1430
27. Ash D., and Hoskin P. Prostate cancer: Permanent seed brachytherapy and high dose rate afterloading brachytherapy. In: Hoskin P., and Coyle C. (Eds). Radiotherapy in practice (2005), Brachytherapy, Oxford, UK 116-121
28. Haustermans K.M., Hofland I., van Poppel, et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys 37 (1977) 1067-1070